Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-01-10 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for January 23, 2024. The purpose of the meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2023. The document also mentions the closure of the trading window for designated persons until 48 hours after the declaration of these financial results. The document is short (1850 characters) and serves as an intimation or announcement rather than containing the financial results or detailed report itself. It is a regulatory announcement related to board activities and financial result scheduling, but it does not contain the actual financial data or report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice under SEBI regulations.
2024-01-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2023. It is addressed to stock exchanges and signed by the Company Secretary. The document is short (1290 characters) and primarily serves as a certification of compliance rather than containing financial data or detailed report content. According to the Certification Rule, such officer certifications or compliance certificates should be classified as Regulatory Filings (RNS).
2024-01-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the closure of the trading window pursuant to SEBI regulations ahead of the announcement of unaudited financial results for the quarter and nine months ended December 31, 2023. It does not contain any financial data or results itself, nor does it present a report. It is an announcement related to insider trading restrictions before the financial results are declared. The document length is short (1752 characters), and it serves as a regulatory notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other categories.
2023-12-28 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of tentative approval from the USFDA for an Abbreviated New Drug Application (ANDA) for Canagliflozin Tablets by Indoco Remedies Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to material events or information. The document does not contain financial statements, detailed financial analysis, or comprehensive report data. It is a regulatory disclosure about a significant business development (product approval) rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-12-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 85% confidence The document is a letter addressed to stock exchanges informing them about the schedule of upcoming analyst and institutional investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of planned investor meetings, not a financial report, earnings release, or detailed presentation. The document length is short (1917 characters), and it does not contain financial data or detailed analysis. It is an update on investor relations activities, specifically the schedule of analyst/institutional investor meetings. This fits best under Investor Presentation (IP) category, as it relates to investor meetings and presentations, although it is a notice of schedule rather than the presentation itself. However, since it is about investor meetings and not a formal report or earnings release, and given the options, the closest classification is Investor Presentation (IP).
2023-11-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them about the schedule of analyst and institutional investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events and information. The content is about informing the exchanges of upcoming investor conferences and meetings, with no financial data, results, or detailed reports included. The document length is short (1898 characters), and it serves as an announcement rather than a report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2023-11-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.